Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H49N7O8 |
Molecular Weight | 683.795 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]3CCC(=O)N3)C(O)=O
InChI
InChIKey=RFDMQNKNNCOSFL-FWEHEUNISA-N
InChI=1S/C34H49N7O8/c1-2-3-4-5-6-14-29(43)36-17-10-9-13-25(34(48)49)39-32(46)26(18-21-20-37-23-12-8-7-11-22(21)23)40-33(47)27(19-28(35)42)41-31(45)24-15-16-30(44)38-24/h7-8,11-12,20,24-27,37H,2-6,9-10,13-19H2,1H3,(H2,35,42)(H,36,43)(H,38,44)(H,39,46)(H,40,47)(H,41,45)(H,48,49)/t24-,25-,26-,27-/m0/s1
Molecular Formula | C34H49N7O8 |
Molecular Weight | 683.795 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
SIS Shulov Innovative Science is developing ZEP 3, a short synthetic peptide. This drug was studied in phase II clinical trial for the treatment of cold sores (Herpes labialis). In addition, was shown that ZEP-3 exhibited analgesic activity in various indications such as osteoarthritis, herpes labialis and ocular pain. In parallel, the company is planning a phase II clinical study in atopic dermatitis.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02483182
ZEP-3 ointment 1.0%
Route of Administration:
Transdermal
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:09:18 GMT 2023
by
admin
on
Sat Dec 16 12:09:18 GMT 2023
|
Record UNII |
0L93DJI2CP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1026276-22-1
Created by
admin on Sat Dec 16 12:09:19 GMT 2023 , Edited by admin on Sat Dec 16 12:09:19 GMT 2023
|
PRIMARY | |||
|
0L93DJI2CP
Created by
admin on Sat Dec 16 12:09:19 GMT 2023 , Edited by admin on Sat Dec 16 12:09:19 GMT 2023
|
PRIMARY | |||
|
9896260
Created by
admin on Sat Dec 16 12:09:19 GMT 2023 , Edited by admin on Sat Dec 16 12:09:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Drugs: ZEP 3(Primary), Aciclovir; Indication: Herpes labialis; Focus: Therapeutic Use; Sponsor: SIS - Shulov Innovative Science; Most Recent Events: 29 Sep 2015 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016 as per ClinicalTrials.gov record., 29 Sep 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016 as per ClinicalTrials.gov record., 29 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
|
||
|
ACTIVE MOIETY |
Originator: SIS - Shulov Innovative Science; Class: Analgesic, Antiviral, Peptide, Skin disorder therapy; Mechanism of Action: Virus replication inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase II for Herpes labialis, Phase I for Herpes virus infections; Most Recent Events: 01 Sep 2015 Phase-II clinical trials in Herpes labialis in Israel (Topical, ointment) (NCT02483182), 30 Jun 2015 SIS Shulov Innovate Science plans a phase II trial for Herpes labialis in Israel (NCT02483182), 01 Feb 2014 SIS Shulov Innovate Science completes a phase I trial in healthy volunteers in Israel (NCT01863160)
|
||
|
ACTIVE MOIETY |
Official Title: A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).
Purpose: This is a phase II, prospective, randomized, double-blind, parallel group, acyclovir-controlled clinical study to evaluate the safety, tolerability and preliminary therapeutic efficacy of ZEP-3 ointment 1.0% for the treatment of cold sores (Herpes labialis), following five consecutive treatment days with five times daily topical administration.
|